Skip to the content
Pictorlogo darklogo light
  • Human Health
    • SARS-CoV-2 Antibodies
  • Animal Health
    • Johne’s Disease / MAP
    • Mycoplasma bovis
  • Technology
    • Multiplex Solution
    • eIFUs & Downloads
  • About
    • About Pictor
    • Our People
    • Our Board
  • News
  • Contact Us
  • Investors
Pictor
  • Human Health
    • SARS-CoV-2 Antibodies
  • Animal Health
    • Johne’s Disease / MAP
    • Mycoplasma bovis
  • Technology
    • Multiplex Solution
    • eIFUs & Downloads
  • About
    • About Pictor
    • Our People
    • Our Board
  • News
  • Contact Us
  • Investors
Pictor
  • Human Health
    • SARS-CoV-2 Antibodies
  • Animal Health
    • Johne’s Disease / MAP
    • Mycoplasma bovis
  • Technology
    • Multiplex Solution
    • eIFUs & Downloads
  • About
    • About Pictor
    • Our People
    • Our Board
  • News
  • Contact Us
  • Investors
7 February 2024
Animal HealthHuman HealthPRESS RELEASETechnology

Disrupting a market, not creating one

Categories
  • Animal Health (3)
  • Human Health (5)
  • PRESS RELEASE (7)
  • Technology (2)
Tags

Awanui Group Bovine Clinical Trials CoVID-19 Investment k1w1 K One W One Marko Bogoievski Mobility Health PRESS RELEASE SARS-CoV-2 Scienion Sir Stephen Tindall Tasso

Head Office
Pictor Ltd.

24 Balfour Road, Parnell, Auckland 1052, New Zealand


NZ +64 9 3090950

info@pictordx.com

Pictor products are manufactured in ISO 13485:2016 certified facilities.

3770 Tansy St, Suite #101, San Diego, CA 92121, United States

US +1-800-641-1096

Pictor products are manufactured in ISO 13485:2016 certified facilities.

  • Linkedin
  • Facebook
  • Twitter
  • Instagram

© 2022 Pictor Limited, All Rights Reserved.

Site by Memory Partners

Back to top